Solid Biosciences was expected to ride gene therapy’s wave of recent momentum to an IPO this week. But the offering, possibly for more than $130 million, did not go off as planned last night, and the company revealed this morning that its most advanced drug candidate has been under FDA scrutiny since mid-November.
The gene therapy, SGT-001, is being developed to treat Duchenne muscular dystrophy, an inherited disease that affects boys, often robbing them of the ability to walk in their teens and killing them at a young age. Now that the FDA has approved its first-ever gene therapy,… Read more »
UNDERWRITERS AND PARTNERS